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Mouse models have been widely used to elucidate
the pathogenic mechanisms of human diseases. The
advantages of using these models include the ability
to study different stages of the disease with particular
respect to specific target organs, to focus on the role
of specific pathogenic factors and to investigate the
effect of possible therapeutic interventions. Sjögren’s
syndrome (SS) is a systemic autoimmune disease,
characterised by lymphocytic infiltrates in the salivary
and lacrimal glands. To date, effective therapy is
not available and treatment has been mainly
symptomatic. Ongoing studies in murine models are
aimed at developing more effective and targeted
therapies in SS. The heterogeneity of SS will most
probably benefit from optimising therapies, tailored
to specific subgroups of the disease. In this review,
we provide our perspective on the importance of
subdividing SS patients according to their interferon
signature, and recommend choosing appropriate
mouse models for interferon-positive and interferon-
negative SS subtypes. Murine models better
resembling human-disease phenotypes will be
essential in this endeavour.genic factor, we discuss how the currently used mouseIntroduction to Sjögren’s syndrome
Sjögren’s syndrome (SS) is a systemic autoimmune
disease characterised by lymphocytic infiltrates in saliv-
ary and lacrimal glands, sialadenitis and dacryoadenitis
respectively. The disease can occur alone − primary
Sjögren’s syndrome (pSS) − or together with other sys-
temic autoimmune diseases such as systemic lupus* Correspondence: n.maria@erasmusmc.nl
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arthritis − secondary SS. The prevalence of pSS is esti-
mated to be between 0.05 and 1%, with a ninefold
predominance in females. Characteristic symptoms are
dry eyes (keratoconjunctivitis sicca) and mouth (xeros-
tomia), with frequent presence of multiple extraglandu-
lar manifestations, such as vasculitis, severe fatigue and
multiorgan involvement [1–3]. At present, no common
evidence-based intervention therapy is available and
treatment is mainly symptomatic. Thus, further unravel-
ling the pathophysiology of pSS is essential for finding
novel biomarkers and identifying new treatment targets.
Murine models are a sophisticated way to model com-
plex pathogenic mechanisms for diseases such as SS,
despite discrepancies in the immune system between
human and mouse [4]. These models provide the oppor-
tunity to manipulate disease processes and look at mul-
tiple organs in depth during the early disease state as
well as disease progression, which is particularly difficult
to achieve in humans but is essential in developing new
therapeutic strategies. Recently, an extensive update on
SS-like murine-models was published in this journal [5].
Here we focus on the present knowledge of the patho-
genesis of human pSS with special regard to the interferon
(IFN) signature. As IFN type I is a suggested key patho-
models fit with subdividing patients into IFN-positive and
IFN-negative subgroups. Taking this subdivision as a start-
ing point we also recapitulate relevant disease features
and interventional studies in the nonobese diabetic
(NOD) mouse model, which is the most commonly used
SS mouse model.Sjögren’s syndrome: from man to mouse
Over the past decade, vast evidence for a role of IFN
type I in the pathogenesis of pSS has emerged. We and
others have described the presence of an IFN type I sig-
nature, assessed as upregulation of a distinct set of IFNicle distributed under the terms of the Creative Commons Attribution License
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lence of the systemic IFN type I signature in over one-
half of pSS patients (referred to as IFN-positive pSS),
identifying a subgroup of patients with higher European
League Against Rheumatism Sjögren’s Syndrome Disease
Activity Index (ESSDAI) scores, presence of anti-Sjögren’s
syndrome-associated autoantigen SSA (Ro52 and Ro60)
and/or anti-Sjögren’s syndrome-associated autoantigen
SSB (La) autoantibodies, higher immunoglobulin (Ig) G
and B-cell activating factor (BAFF) levels, and lower C3
complement levels [10]. The abundant presence of auto-
antibodies leading to circulating immune complexes (ICs)
is thought to be the main trigger inducing the IFN signa-
ture in pSS and SLE [13].
In addition to IFN type I, novel evidence indicates IFN
activation in SS glands to be partly attributed to IFN
type II activity (IFNγ) [14]. Whether this also holds true
for systemic IFN activation in pSS remains to be estab-
lished. A recent study in SLE, however, revealed distinct
systemic type I and type II signatures [15]. Fig. 1 depicts
the multifactorial pathogenesis of pSS, where IFNs are
centred as the main culprits in the self-amplifying patho-
genic loop. Better understanding of these distinct IFN
pathways is crucial in selective therapeutic targeting.
Here we provide our perspective on the importance of
subdividing pSS patients according to their IFN signa-
ture. To better resemble the human situation we will
need to find models best fitting our subdivision, where
one can be used as an IFN-negative model and the other,
possibly accelerated by triggering the IFN system, can be
used as its IFN-positive counterpart.
Interferon-related murine models as
interferon-positive Sjögren’s syndrome
As IFNs play an eminent role in human pSS pathogen-
esis, we studied the NOD mouse model for the presence
of systemic IFN activation and found no indication for
the presence of a systemic IFN signature (McGuiness B,
Beumer W and colleagues, unpublished work). We there-
fore suggest the NOD mouse to be systemically IFN-
negative, and set out to look at some previous studies
in murine models for a possible IFN-positive counter-
part. Many systemic autoimmune models used for SLE,
amongst other diseases, extensively direct their attention
to IFNs and their role in autoimmune development
[13, 16–18]. Here we highlight existing autoimmune mur-
ine models which in our opinion are models to be revis-
ited for potential SS-like disease.
Interferon-inducible models in murine autoimmunity
External triggering of the IFN system in order to mimic
systemic IFN overactivation is an approach often used in
autoimmune-prone mice. Interestingly, the group of
Deshmukh and colleagues applied this strategy to thelupus-prone New Zealand Black/White F1 mouse strain
to study SS-like disease. After treatment of the mice with
Toll-like receptor (TLR)-3 agonist poly(I:C), chronic
systemic activation accelerated sialadenitis [19]. Interest-
ingly, in addition to TLR3, poly(I:C) also engages the nu-
cleic acid sensors retinoic acid-inducible gene I (RIG-I;
DDX58) and melanoma differentiation associated antigen
5 (MDA5; IFIH1). These retinoic acid-inducible gene-like
helicases have recently been suggested to collaborate with
endosomal TLRs in amplifying IFN overactivation (see
Fig. 1) [20–22], and thus might also contribute to overacti-
vation of IFN in the poly(I:C)-treated mice. Retinoic
acid-inducible gene-like helicases might be relevant thera-
peutic targets.
New Zealand Mixed (NZM) 2758 mice were addition-
ally demonstrated to develop SS-like disease, after prior
triggering of innate immunity by alum and induction of
antibodies by immunisation with Ro52. This recent
study focused on Ro52-induced salivary gland dysfunc-
tion and hypothesised that autoantibody deposition in
the glands might be crucial to induce xerostomia and
SS-like disease [23]. However, the role of IFNs in disease
induction was not assessed.
Imbalanced Toll-like receptor signalling leads to murine
autoimmunity
For the generation of autoantibodies by B cells and IC-
mediated IFN production by plasmacytoid dendritic
cells, myeloid differentiation primary response gene 88
(MyD88)-dependent endosomal TLR7 and TLR9 are
crucial. Nucleic acid-sensing TLRs such as TLR3, TLR7,
TLR8 and TLR9 are located in intracellular endosomal
compartments, consequently minimising possible expos-
ure to self-antigens [24]. Intriguingly, our group recently
found that the TLR7 pathway was upregulated in periph-
eral blood cells of IFN-positive pSS, whereas TLR9 was
not (NI Maria and colleagues, unpublished work). A
similar imbalance in TLRs was observed in murine lupus
models. Opposing effects were described for TLR7 and
TLR9: deletion of TLR7 limited autoimmunity, whereas
TLR9 deletion paradoxically exacerbated disease. TLR7
deletion prevented RNA-associated antibody formation,
whereas TLR9 deletion resulted in increased systemic in-
flammation and IC-induced glomerulonephritis [18].
That controlling TLR7 expression is essential in restrict-
ing autoimmunity already became clear when TLR7 gene
duplication was demonstrated to be the sole require-
ment for accelerated autoimmunity in B6.Yaa mice. A
substantial TLR7 increase even caused fatal acute in-
flammatory pathology and extensive dendritic cell dys-
regulation [16]. This mouse model, portraying the Yaa
phenotype (TLR7 gene duplication; BXSB/MpJ-Yaa), was
recently described to develop autoimmune dacryoadeni-
tis in a study focusing on SS-like features [25], showing
Fig. 1 Multifactorial pathogenesis of primary Sjögren’s syndrome: interferons as culprits in the self-amplifying pathogenic loop. A damage trigger
such as stress or infection leads to accumulating apoptotic debris, inducing rapid interferon (IFN) type I production by plasmacytoid dendritic cells
(pDCs). IFN type I then binds to IFNα,β receptor (IFNAR) on adjacent target cells, which induces an IFN signature and IFN-primed mature effector
cells, amongst others, by perpetuating the TLR7 pathway in autoreactive plasma cells as well as self-amplification in the pDCs. TLR7 upregulation
in autoreactive plasma cells increases RNA-associated autoantibody production (SSA/Ro52, SSA/Ro60 and SSB/La). These RNA-associated
autoantibodies form immune complexes together with self-apoptotic debris, further triggering the TLR7 pathway. Prolonged inflammation can
lead to exhaustion of the complement system with decreased complement-mediated solubilisation and further accumulation of immune
complexes. Neutrophils can cause further tissue damage by forming neutrophil extracellular traps, these netting neutrophils also being potent
inducers of IFN type I production. Autoantibodies induce netting of IFN-primed neutrophils, further amplifying the loop. IFN-primed dendritic cells
(DCs) activate T cells, as well as natural killer and natural killer T cells (data not shown), to produce vast amounts of IFN type II (IFNγ). Although
TLRs are widely considered the usual suspects in autoimmune pathophysiology, recently the cytoplasmic RIG-I-like family of helicases (RLHs),
RIG-I (DDX58) and MDA5 (IFIH1) have been gaining the spotlight as co-conspirators. Evidence points towards a collaborative effort between TLRs and
RLHs, together enhancing inappropriate self-recognition and sustained IFN overactivation. IFIH1 upregulation has been identified in IFN-positive pDCs
of primary Sjögren’s syndrome patients (unpublished data), as previously in glands of Sjögren’s syndrome-like (C57BL/6.NOD-Aec1Aec2) mice [61].
This IFN-driven pathogenic loop in primary Sjögren’s syndrome, in part driven by aberrant sensing of nucleic acids, can potentially lead to functional
decline or even loss of function in target tissues. APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor; IL, interleukin; MDA5, melanoma
differentiation-associated protein 5; MHC, major histocompatibility complex; RIG-I, retinoic acid-inducible gene 1; Th17, T-helper type 17; TLR, Toll-like
receptor; Treg, regulatory T cells
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immune models for SS.
The imbalance in endosomal TLRs, which results in
much more prominent lupus-like disease compared with
wild-type (WT) mice, was also recently shown using
mice deficient in TLR8 and/or TLR9. TLR8 deficient
mice (B6.TLR8−/−) and particularly double TLR8/9-defi-
cient mice (B6.TLR8/9−/−) displayed marked induction
of TLR7, which was associated with more severe disease.
This study concludes that both TLR8 and TLR9 act to-
gether in controlling TLR7 function, TLR8 particularly
controlling TLR7 function in dendritic cells and TLR9
restraining TLR7 response in B cells [17].
Other potential TLR-related models to be revisited
are reviewed elsewhere [13], elaborating on possibilities
for exacerbated renal disease in TLR9−/− versus re-
duced disease in their TLR7−/− counterpart. TLR9-
deficient autoreactive B cells no longer undergo class
switching to pathogenic immunoglobulin isotypes
(IgG2a and IgG2b), these TLR9−/− mice having signifi-
cantly smaller IgG deposits in the glomeruli and a pro-
longed survival compared with their TLR9 sufficient
littermates. In contrast, TLR7-deficient mice no longer
produce RNA-specific autoantibodies, developing less
severe clinical disease than their TLR7 sufficient litter-
mates [13].
Further investigating this imbalanced endosomal TLR
signalling in IFN-driven pSS is warranted because most
studies focus on SLE. The above mentioned murine
models will be crucial in this endeavour, as the tight
regulation of TLR7 is preventing autoreactivity leading
to autoimmunity.
Toll-like receptor inhibitors in interferon-related
autoimmunity
The antimalarial agent hydroxychloroquine has long
been considered an effective treatment for SLE and is
frequently used for pSS. Chloroquines are said to block
TLR7/9 activation either by preventing acidification and
maturation of the endosomes or by interacting with nu-
cleic acids and thereby preventing TLR triggering. The
exact mechanisms and effects of chloroquines remain
controversial (reviewed in [24]), and the effect of other
TLR-blocking agents needs to be evaluated. In fact, a
recent clinical trial evaluating the efficacy of hydroxy-
chloroquine for the main symptoms of pSS concluded
that 24 weeks of treatment with hydroxychloroquine did
not improve symptoms compared with placebo. As the
authors conclude, further studies are indeed warranted
to determine longer-term outcomes of hydroxychloro-
quine use [26].
In a recent study, New Zealand Black/White F1 mice
were treated with a TLR7/8/9 antagonist. Treated mice
had lower serum autoantibody levels, reduction inproteinuria and kidney histopathology compared with
their untreated counterparts [27]. Interestingly, small-
molecule dual TLR7/9 antagonists are currently being
tested in SLE patients; however, selective TLR7 inhib-
ition might be a more promising approach and should,
in our opinion, be evaluated in SS-like murine models
for therapeutic efficacy.
Targeting interferons and the IFNα,β receptor
The IFN type I family of cytokines comprises 17 sub-
types, all signalling through a common receptor, the
IFNα,β receptor (IFNAR). Blocking one single subtype
with specific monoclonal antibodies has not shown the
promising results anticipated in SLE trials, thus directly
blocking the IFNAR might prove more beneficial. This ap-
proach is supported by a study showing that deletion of
Ifnar1 prevented severe disease in at least two lupus-
prone strains. Interestingly, monoclonal antibodies against
human IFNAR are currently tested for effectivity in SLE
and systemic sclerosis [28, 29]. Recently, B6.IFNAR−/−
mice and WT mice triggered with IFN-inducing poly(I:C)
were tested for salivary gland hypofunction. Loss of glan-
dular function was evident in WT mice and limited in
IFNAR−/− mice, thus indicating a crucial role for IFN type
I in xerostomia [30]. This observation points towards
possible therapeutically beneficial effects in blocking the
IFNAR in pSS.
Type I and type II IFNs signal via different receptors
but share overlapping patterns of activated genes down-
stream. A recent study in human salivary gland tissue
provided evidence that IFN type II (IFNγ) also contrib-
utes to the IFN signature in SS glands, and therefore the
role of IFNγ needs to be further investigated in humans
and mice. Interestingly, Ro60 peptide-immunised Balb/c
mice significantly developed increased levels of IFNγ
which correlated to decreased salivary flow [31], but the
effect of increased IFNγ on a systemic IFN signature re-
mains to be analysed.
Autoantibodies and the BAFF/APRIL system in murine
autoimmunity
IFN type I itself has vast effects on B-cell survival, pos-
sibly perpetuating the pathogenic loop. IFNs induce
BAFF and a proliferation inducing ligand (APRIL) expres-
sion in monocytes, thereby contributing to antibody-
producing plasma cell survival resulting in prolonged
pathogenic autoantibody production. This further triggers
IFN signalling as well as increased IC deposition in target
tissues leading to chronic inflammation, damage and, ul-
timately, loss of function [32]. A recent study looking into
the necessity of individual BAFF receptors BCMA, TACI
and BR3 in receptor-deficient NZM 2328 mice concluded
that any single BAFF receptor could be dispensable for
lupus development in their model [33]. An earlier study
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NZM 2328 mice were largely spared from clinically overt
disease. These mice only showed serological autoimmun-
ity and renal pathology, whereas severe proteinuria and
mortality were greatly reduced. Blocking BAFF might thus
not fully reverse or eliminate underlying pathology, but
seemingly leads to substantial clinical improvement in
murine autoimmunity [34].
The study by Mackay and colleagues illustrates that
our view on revisiting lupus-prone mouse models for
SS pathology is a rewarding approach. In BAFF trans-
genic mice, considered a model for SLE, they observed
SS-like disease characterised by severe sialadenitis, de-
creased saliva production and destruction of subman-
dibular glands [35].
Supporting an important role for autoantibodies in
pSS is a recent study performed in mice lacking the
SLE and pSS autoantigen Ro52/TRIM21. After local
damage induction by ear tagging, Ro52/TRIM21−/−
mice develop a lupus-like phenotype. Ro52/TRIM21 in-
teracts with IFN regulatory factors that play a role in
tightly regulating IFN signalling. In these mice, cellular
damage drives pathology via potential triggering of
endosomal TLRs through enhanced IFN production
[36]. Ro52-targeted autoantibodies produced by auto-
reactive B cells might be interfering with the important
regulatory role of Ro52/TRIM21 in maintaining bal-
anced IFN signalling.Biologicals targeting the BAFF/APRIL system
Observations in lupus-prone mice led to rapid develop-
ment of biologicals interfering with the BAFF/APRIL
system such as belimumab (anti-BAFF) and atacicept
(dual BAFF/APRIL inhibitor) [37]. Treatment of mice
with rapidly progressive glomerulosclerosis in both early
and late stages of disease with BAFF-Ig or TACI-Ig re-
vealed that selective BAFF blockade was sufficient to
both prevent disease development and progression. This
led to the conclusion that both treatments were equally
effective in retaining remission by prolonged B-cell
depletion and a decrease in inflammatory response to
renal IC deposition [38]. However, when disease was ac-
celerated by IFNs, BAFF blockade only proved beneficial
in the initiation phase and did not prevent progression
once autoantibodies were present. These biologicals
might not be sufficiently effective in later disease stages
in autoantibody-positive patients and additional therap-
ies targeting the pathways activated by IFN might be
essential additives. Presently, belimumab is tested in hu-
man pSS, showing encouraging results. The belimumab
in patients with pSS BELISS trials justify future studies
with the BAFF-targeting drug in the autoantibody-
positive subset of pSS [39, 40].The nonobese diabetic mouse model as
interferon-negative Sjögren’s syndrome
Nonobese diabetic and NOD-derived strains as spontaneous
models for Sjögren’s syndrome
Apart from spontaneously developing diabetes, female
NOD mice recapitulate typical SS-like symptoms such
as decreased salivary flow and lymphocytic infiltrates in
salivary glands [41, 42]. In contrast to inducible models
for autoimmunity, NOD mice follow a pattern of initial
morphological changes in the salivary glands prior to the
onset of focal infiltration and manifestation of clinical
symptoms at about 16 weeks of age [43, 44]. Furthermore,
the disease profile in NOD mice resembles human SS
concerning composition of infiltrates in salivary glands
and partially in terms of the autoantibody profile [45].
Additionally, NOD mice develop lymphocytic infiltrates in
the lacrimal glands and interestingly this dacryoadenitis
develops more frequently in males. Microarray analysis on
lacrimal glands of male NODs resulted in the identifica-
tion of cathepsins as candidate biomarkers for SS [46, 47].
Initial infiltrating immune cells were found to be respon-
sible for this increased cathepsin expression, thereby initi-
ating lacrimal gland remodelling and degradation [48].
Interestingly, cathepsin expression increased in parallel
with proinflammatory cytokines during autoimmune de-
velopment in the male NODs [46]. In general, however,
studies on lacrimal glands in NOD mice are rare and truly
deserve more attention.
Autoimmune manifestations in NOD mice develop
through a complex interplay of several factors composed
of genetic predisposition and intrinsic immune dysfunc-
tions which manifest under the influence of environmen-
tal conditions [49]. NOD mice develop diabetes in a major
histocompatibility complex (MHC) class II-dependent
manner prior to autoimmune exocrinopathy. Changing
the MHC class II haplotype can protect NOD mice from
developing diabetes but not SS-like disease, and can affect
the severity of sialadenitis [50, 51]. Association of SS with
genes encoding for human leukocyte antigen has been re-
ported [52], and thus indicates the importance of the
MHC haplotype.
Although T cells are the dominant type of lymphocytes
found in the infiltrates, SS is thought to predominantly
be a B-cell-mediated disease. NOD-Igμnull mice, which
lack functional B cells, show the typical lymphocytic in-
filtrations in the salivary glands but do not develop
hyposalivation until transfer of purified human SS-IgG
or parental NOD-IgG, suggesting a crucial role for anti-
bodies in an overt clinical stage of the disease rather
than the initial phase of lymphocyte infiltration [53].
Transient depletion of regulatory T cells in NOD mice
(performed at the age of 10 days) showed an accelerating
effect on sialadenitis, while depletion in older mice did
not influence sialadenitis [54]. Moreover, depletion of
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reversed resistance to an autoimmune phenotype and
increased both the presence and size of salivary gland
infiltrations compared with WT NOD mice [55]. These
findings underline the importance of a balanced
regulatory-cell and effector-cell population in different
stages of disease. Nevertheless, how depletion of regula-
tory T cells affects exocrine gland dysfunction remains
to be established because the grade of infiltration does
not correlate with actual dryness. This important point
must be realised because there is also no correlation
between gland function and grade of infiltration in
humans. Studies combining analysis of gland function
and infiltration pattern are therefore warranted.
The development of diabetes and SS-like disease in
NOD mice is accepted to occur as two separate events,
after identification of Idd3 (also termed autoimmune
exocrinopathy 1, Aec1) and Idd5 (also termed auto-
immune exocrinopathy 2, Aec2) as the genetic risk regions
being sufficient for manifestation of exocrine dysfunction
in NOD mice [56]. Introduction of Idd3 and Idd5 loci
from NOD in the nonautoimmune prone C57BL/6 strain
resulted in the so-called C57BL/6.NOD-Aec1Aec2 strain,
which develops SS-like disease but not diabetes. Compar-
able with human SS, SS-like disease in C57BL/6.NOD-
Aec1Aec2 mice is initiated by a preclinical silent phase be-
fore the onset of overt disease [57, 58]. A study comparing
human SS parotid gland tissue with salivary glands of
Aec2/Aec2 mice revealed common dysregulated path-
ways − associated with leukocyte recruitment and germi-
nal centre formation [59] − underlining the relevance of
the model for testing novel therapeutics.
The interferon signature in NOD and NOD-derived strains
As described above, upregulation of IFN inducible genes
termed the IFN signature has been observed both in
target tissue and systemically in pSS patients [10, 60].
However, it is important to realise that observations in
salivary glands do not imply that an IFN signature is sys-
temically present.
The comparison of salivary gland IFN signatures in
murine SS-like disease and human SS has been reviewed
recently and clearly reveals expression of IFN type I in-
duced genes in human pSS and NOD salivary glands
[61, 62]. Interestingly, microarray analysis of male NOD
lacrimal glands did not reveal increased IFN type I ex-
pression [46]. However, it is debatable whether data
from murine glands can be compared with human per-
ipheral blood studies. It is thus peculiar that most mur-
ine SS-like studies are focused on the IFN signature in
the exocrine glands, fully disregarding the systemic as-
pect of the disease. We evaluated the gene expression
patterns of NOD monocytes at various time points of
disease development and found no evidence for systemicIFN type I activation (McGuiness B, Beumer W and
colleagues, unpublished work). Hence, it should be
mentioned that studies in human pSS simultaneously
analysing the IFN signature in salivary glands and per-
ipheral blood are still lacking. Therefore, there may well
be pSS patients with local IFN type I activation in the
glands but lacking systemic IFN type I activity, similar to
NOD mice.
The pathogenic effect of IFN type I was assessed
in C57BL/6.NOD-Aec1Aec2 mice deficient for Ifnar1
(B6.Aec1Aec2Ifnr1−/−) and thus unable to respond to
IFN type I-mediated signalling [63]. B6.Aec1Aec2Ifnr1−/−
mice did not upregulate IFN-responsive genes in the
submandibular glands in comparison with their WT
counterparts, although only a limited number of targets
were tested in this study. Most strikingly, these mice were
protected from salivary gland dysfunction and showed re-
duced infiltration in salivary and lacrimal glands, even
though they still generated a robust systemic autoantibody
response. Taken together, these findings support the hy-
pothesis that systemic and local IFN activation can occur
as two separate events.
Although type I IFNs were initially thought to be the
driving force for the IFN signature, both IFN type I and
type II activity were detected in human pSS salivary
gland biopsies [14], while in pSS a contribution of type
II to the systemic IFN signature remains to be estab-
lished. In submandibular glands of NOD mice it has
clearly been demonstrated that IFN type II/IFNγ partici-
pates in the early onset of SS-like disease. NOD.IFNγ−/−
and NOD.IFN-γR−/− mice fail to develop sialadenitis,
although retaining lymphocytic infiltrates in the lacrimal
glands [64]. Nevertheless, to date these findings remain
limited to local similarities. Thus, although there are
many overlapping features between human pSS and
NOD mice, evidence for a systemic IFN type I signature
as observed in more than 50% of the human pSS pa-
tients is lacking in NOD mice. We conclude that NOD
and NOD-derived strains rather represent the subset of
systemically IFN-negative SS patients, and could contrib-
ute significantly to insights into the pathogenesis of IFN-
negative pSS patients.
Interventional studies in NOD and NOD-derived strains
Over the past years, several intervention studies have
been performed on NOD or NOD-derived models, most
of them using C57BL/6.NOD-Aec1Aec2 as a model for
SS. Owing to space limitations, we selected from the
large number of studies those that were tested in clinical
trials or are in our view interesting candidates for trans-
lation into clinics.
Development of malignant lymphomas is a risk in pSS
and therefore studies on mechanisms of malignant trans-
formation are important. Lymphoid structure formation
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human pSS [65]. To evaluate the inhibitory effect on
lymphoid structure formation in exocrine glands of NOD
mice, blockage of the lymphotoxin-beta receptor (LTBR)
pathway by injection of LTBR-Ig was performed. LTBR
blockage ablated lymphoid structures and reduced salivary
gland tissue degeneration and lacrimal gland pathology,
whereas salivary flow was partially restored [66, 67].
Nevertheless, injection of LTBR-Ig was performed in an
early disease stage, and thus the effect on disease progres-
sion when administered in a late, overt disease phase re-
mains to be tested.
The manipulation of co-stimulatory mechanisms by
local gene therapy gave less conclusive results. Attempts
to inhibit CD40 ligation in NOD mice did not alter SS-
like disease at all [68], whereas CTLA-4-IgG expression
in C57BL/6.NOD-Aec1Aec2 mice improved sialadenitis
and salivary gland function [69]. At present, CTLA-4-
IgG is being tested in clinical trials.
Several gene therapy-based studies targeting different
SS-related cytokines were performed. In C57BL/6.NOD-
Aec1Aec2 mice, targeting of interleukin (IL)-17 produc-
tion by T-helper (Th) 17 cells locally in the salivary
glands led to improved SS-like disease, independent of
the disease state at administration [70]. Accordingly, sys-
temically administered gene therapy using IL-27 to inhibit
Th17 activity was performed in C57BL/6.NOD-Aec1Aec2
mice in early and advanced disease stages. The treatment
did not alter lymphocytic infiltration but resulted in less
severe clinical disease manifestation [71]. Overall, target-
ing Th17 networks might be a useful treatment option.
Recently the role of the cytokine IL-7, elevated in
human-SS, has been analysed using C57BL/6.NOD-
Aec1Aec2 mice. IL-7 was found to enhance the Th1
response and to promote the development of SS-like dis-
ease, whereas IL-7 blockade had a disease-ameliorating
effect. Furthermore, IL-7 was found to influence Th1 re-
sponses via IFNγ activation [72]. Interestingly, IL-7 and
TLR7 seem to act synergistically on T-cell and B-cell ac-
tivation. Considering the importance of TLR7 activation
in autoimmunity, IL-7 should be considered a future
candidate for intervention studies [73]. Besides TLR7,
TLR9 seems to be involved in the pathogenesis of SS-like
disease in NOD mice. Activation of TLR9-dependent p38
mitogen-activated protein kinase was recently found to
occur in an early disease state [74]. However, agonistic
TLR9 treatment that activated the alternative nuclear
factor-κB pathway increased salivary flow [75]. These
findings support a crucial role for the TLR7/9 balance,
where increased TLR9 signalling potentially salvages auto-
immunity whilst a tilt towards TLR7 signalling actually ex-
acerbates autoimmunity.
Taking these results together, it is important to note
that the stage of SS-like disease in NOD mouse modelsstrongly influences the outcome of different therapeutic
interventions. The majority of treatments tested in mice
were performed at an early disease stage. Intervening
when overt disease is present in relevant animal models
is required before these approaches are applicable in
humans. Besides, human SS is mostly diagnosed in an
overt phase.
Perspectives: from mouse to man
When drawing conclusions from mouse models for clin-
ical relevance in humans, a proper understanding of
both the similarities and differences in immune function
between mouse and man remains crucial for adequate
interpretation of mouse studies [4]. There is ongoing
controversy when using murine models regarding appro-
priate extrapolation of obtained knowledge into a clinical
setting. We therefore propose the best strategy to be a
back and forth interplay between mice and men. Revisit-
ing existing mouse models in a more disease-related way
certainly might help to elucidate underrated aspects of
the disease. In particular, lupus-prone models that can
be used for SS might reveal novel insights into SS patho-
genesis. Here we aimed to highlight this approach, loop-
ing the circle from mouse to man and back (see Fig. 2).
As SS in humans is very heterogeneous, multiple ani-
mal models are necessary to fully elucidate disease path-
ogeneses. Subtyping disease according to the prominent
pathogenic player IFN, according to the IFN signature, is
therefore a crucial first step. We highly recommend
choosing appropriate mouse models for both IFN-
negative and IFN-positive disease subtypes in future
studies. In particular, we suggest NOD as a model for
systemically IFN-negative SS. Recently, evidence for dis-
tinct roles of IFN type II and type III in autoimmunity
has emerged [14, 15, 76], probably making subtyping
even more complex in the near future but also much
more effective for strategic therapeutic targeting.
In terms of developing new approaches for therapeutic
interventions, the TLR–IFN network is a promising tar-
get and warrants more in-depth investigation. The deli-
cate balance between endosomal TLRs appears crucial
to prevent autoimmunity, and a better understanding of
these pathways and how they are balanced will provide
insight into specific targeted therapies [77]. Interestingly,
tackling TLR7 will have effects on both plasmacytoid
dendritic cells and B cells simultaneously, and might
prove beneficial by inhibiting multiple aspects of the dis-
ease with one compound. Whether TLR7 blockade alone
or in combination therapies will prevent and/or amelior-
ate pSS pathogenesis remains to be investigated [13].
Conclusions
The heterogeneity of SS will most probably benefit from
optimising therapies, tailored to specific subgroups of
Fig. 2 Primary Sjögren’s syndrome: a back and forth interplay from mouse to man. To investigate the heterogeneous and complex pathogenesis
of primary Sjögren’s syndrome (pSS), murine models such as nonobese diabetic (NOD) or NOD-derived mice are indispensable. Knowledge-based
implementation derived from mouse models is commonly implemented into human studies and potential clinical trials. As the heterogeneity of
patients is often underestimated, we propose a back and forth interplay of knowledge between mouse and man, looping the circle from man to
mouse and back. Hereby, models will further be improved to better resemble specific aspects of human disease, essential for both therapeutic
development and outcome prediction. An important step will be to compare common deregulated pathways in both mouse and man to
address therapeutic manipulations, by isolating whole blood/peripheral blood mononuclear cells (PBMCs) or extracting target tissue biopsies
from salivary and lacrimal glands. Patient selection and subgrouping according to their interferon (IFN) signatures, into IFN-positive and
IFN-negative subgroups, will require separate mouse models per subgroup. As the NOD mouse most probably represents the subset of systemically
IFN-negative patients, we here propose the NOD model revisited: TLR7-induced systemic IFN signature in the NOD mouse as the IFN-positive
counterpart, by topical application of the TLR-agonist imiquimod. Furthermore, comparing equal compartments in both subgroups of mice and
men will give new insights into both the similarities and differences. Mouse models will remain crucial for preclinical exploration studies and
will need continued revisiting and refining. TLR, Toll-like receptor
Maria et al. Arthritis Research & Therapy  (2015) 17:172 Page 8 of 11the disease. Here we provide our perspective on the
importance of subdividing SS patients according to their
IFN signature, and recommend choosing appropriate
mouse models for IFN-positive and IFN-negative SS
subtypes. Murine models better resembling human-
disease phenotypes will be essential in this endeavour.
Several key messages can be obtained from this review:1. Simultaneous histopathology and functional analysis
of salivary and lacrimal glands in relevant mouse
models will result in further insight into SS
pathogenesis
2. Lupus-prone mouse models should be revisited for
salivary and lacrimal gland pathology and
dysfunction
Maria et al. Arthritis Research & Therapy  (2015) 17:172 Page 9 of 113. A distinction between local and systemic presence of
IFN activity is essential, because local IFN activation
does not directly imply the presence of systemic
IFN activation
4. Therapeutic interventions should be tested when
overt disease is present in relevant animal models,
because pSS is diagnosed in this phase in humans
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